CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...